Cellular Therapy
Conference Coverage
Secondary AML in first remission predicts outcomes
HOUSTON – Secondary AML predicts outcomes after SCT in first complete remission, whereas factors such as age, cytogenetics, and performance status...
Conference Coverage
Haplo-HSCT bests chemotherapy for MRD-positive adult ALL
HOUSTON – Haplo-HSCT outperforms chemotherapy for the treatment of adults with ALL in first complete response, particularly MRD-positive patients...
Conference Coverage
Therapeutic dosing of busulfan helps reduce relapse in ASCT
HOUSTON - Pharmacokinetic-directed therapeutic dose monitoring of busulfan used in combination with cyclophosphamide and etoposide appears to...
Conference Coverage
Anti-CD45 conditioning looks safe, feasible in relapsed AML
HOUSTON – Iomab-B use has resulted in successful engraftment for all patients who have received it and gone on to transplant, despite active...
From the Journals
Weak evidence surrounds use of mesenchymal stem cells
A Cochrane review found weak evidence to support limited use of mesenchymal stem cells in hematopoietic transplant.
Conference Coverage
Engraftment achieved after conditioning without radiation, alkylating agents
HOUSTON – The study of 20 dyskeratosis congenita patients may have implications for other diseases managed by transplant.
Conference Coverage
KD025 produces durable responses in patients with cGVHD
HOUSTON – Many responses have lasted 20 weeks or more, and durability data are still maturing.
Conference Coverage
Lentiviral gene therapy appears effective in X-CGD
HOUSTON – Results from the small study provide a “proof of concept” for the use of gene therapy in X-linked chronic granulomatous disease,...
Conference Coverage
Novel transplant regimen improves survival in primary immunodeficiency
HOUSTON – Allo-HCT following a novel reduced-intensity conditioning regimen was largely successful in an NIH study of adults and children with...
Conference Coverage
Ixazomib targets treatment failure in chronic GVHD
HOUSTON – Most patients in the phase 2 trial had severe chronic graft-versus-host disease and most had received three or more prior lines of...
Feature
Barriers to CAR T use in the spotlight at first European meeting
European approvals of CAR T-cell therapy are prompting a closer look at economic issues, outcomes data, and future directions.